Criteria for the diagnosis of corticobasal degeneration

• DOI: 10.1212/wnl.0b013e31827f0fd1
• Publication Date: 2013-01-29T00:14:53Z
• Authors: Melissa J. Armstrong; Irene Litvan; Anthony E. Lang; Thomas H. Bak; Kailash P. Bhatia; Barbara Borroni; Adam L. Boxer; Dennis W. Dickson; Murray Grossman; Mark Hallett; Keith A. Josephs; Andrew Kertesz; Suzee E. Lee; Bruce L. Miller; Stephen G. Reich; David E. Riley; Eduardo Tolosa; Alexander I. Tröster; Marie Vidailhet; William J. Weiner
• Keywords: Male; Aging; Databases, Factual; Clinical Sciences; 610; Clinical sciences; Neurodegenerative; Alzheimer's Disease; Basal Ganglia; Databases; 03 medical and health sciences; Rare Diseases; 0302 clinical medicine; 616; Acquired Cognitive Impairment; Genetics; Humans; Age of Onset; Alzheimer's Disease Related Dementias (ADRD); Factual; Aged; Retrospective Studies; Cerebral Cortex; Family Health; Neurologic Examination; Language Disorders; Neurology & Neurosurgery; Biomedical and Clinical Sciences; Neurosciences; Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD); Neurodegenerative Diseases; Middle Aged; Brain Disorders; 3. Good health; Frontotemporal Dementia (FTD); Phenotype; Neurological; Dementia; Cognitive Sciences; Female; Cognition Disorders

Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD) no longer reflect the expanding understanding of this disease and its clinicopathologic correlations. An international consortium of behavioral neurology, neuropsychology, and movement disorders specialists developed new criteria based on consensus and a systematic literature review. Clinical diagnoses (early or late) were identified for 267 nonoverlapping pathologically confirmed CBD cases from published reports and brain banks. Combined with consensus, 4 CBD phenotypes emerged: corticobasal syndrome (CBS), frontal behavioral-spatial syndrome (FBS), nonfluent/agrammatic variant of primary progressive aphasia (naPPA), and progressive supranuclear palsy syndrome (PSPS). Clinical features of CBD cases were extracted from descriptions of 209 brain bank and published patients, providing a comprehensive description of CBD and correcting common misconceptions. Clinical CBD phenotypes and features were combined to create 2 sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based pathologies. Probable CBD criteria require insidious onset and gradual progression for at least 1 year, age at onset ≥ 50 years, no similar family history or known tau mutations, and a clinical phenotype of probable CBS or either FBS or naPPA with at least 1 CBS feature. The possible CBD category uses similar criteria but has no restrictions on age or family history, allows tau mutations, permits less rigorous phenotype fulfillment, and includes a PSPS phenotype. Future validation and refinement of the proposed criteria are needed.